tiprankstipranks
Trending News
More News >
Sonova Holding AG (CH:SOON)
:SOON
Advertisement

Sonova Holding AG (SOON) AI Stock Analysis

Compare
9 Followers

Top Page

CH:SOON

Sonova Holding AG

(SOON)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
CHF221.00
▲(10.97% Upside)
Sonova Holding AG's overall stock score reflects strong financial performance and positive earnings call sentiment. However, bearish technical indicators and moderate valuation weigh down the score. The company's ability to maintain growth in key segments and manage challenges in others will be crucial for future performance.
Positive Factors
Strong Revenue Growth
Consistent revenue growth indicates robust market demand and effective business strategies, supporting long-term financial stability and expansion.
Successful Product Launches
Innovative product launches enhance competitive positioning and drive future growth by meeting consumer needs and expanding market share.
Effective Cash Flow Management
Strong cash flow management ensures liquidity and supports reinvestment into growth opportunities, sustaining long-term operational success.
Negative Factors
Challenges in Cochlear Implants
Declining sales in key segments like Cochlear Implants can hinder growth and require strategic adjustments to regain market traction.
Impact of Swiss Franc Strength
Currency fluctuations can adversely affect financial performance, necessitating strategies to mitigate foreign exchange risks.
Gross Profit Margin Challenges
Decreasing profit margins may indicate rising costs or pricing pressures, impacting profitability and requiring cost management strategies.

Sonova Holding AG (SOON) vs. iShares MSCI Switzerland ETF (EWL)

Sonova Holding AG Business Overview & Revenue Model

Company DescriptionSonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication products; rechargeable hearing aids; wireless headsets, speech enhanced hearables, audiophile headphones, microphones, and wireless transmission systems; and audiological care services. It also provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; consumer hearing products under the Sennheiser brand; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton brands. The company sells its products through independent distributors; and provides hearing care services through a network of approximately 3,600 stores and clinics. It operates in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
How the Company Makes MoneySonova generates revenue primarily through the sale of hearing aids and related products, including accessories and batteries. The company operates through multiple distribution channels, including direct-to-consumer sales, partnerships with audiology professionals, and collaborations with healthcare providers. Key revenue streams include the sale of hearing aids, which represents a significant portion of their income, as well as service and maintenance contracts for their devices. Furthermore, Sonova benefits from strategic partnerships with healthcare institutions and audiology clinics, enhancing their market reach and customer base. Factors contributing to their earnings include a strong focus on research and development, enabling the introduction of cutting-edge products, as well as an increasing global demand for hearing solutions driven by an aging population and greater awareness of hearing health.

Sonova Holding AG Earnings Call Summary

Earnings Call Date:Nov 14, 2025
(Q2-2026)
|
% Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Neutral
The earnings call conveyed optimism with strong growth in key segments, successful product launches, and maintained financial outlook. However, challenges in specific segments like Cochlear Implants and Consumer Hearing, along with the negative impact of the Swiss franc, tempered the overall positive narrative.
Q2-2026 Updates
Positive Updates
Strong Sales Growth in Key Segments
Hearing Instruments and Audiological Care saw a combined sales growth of 7% in local currencies, which is around twice the estimated market growth, resulting in significant market share gains.
Record Earnings and Margin Expansion
Normalized EBITA reached CHF 316 million, up 16% in local currencies, leading to a strong margin expansion of 180 basis points.
Successful Product Launches
The launch of Phonak Infinio and Infinio Sphere platforms and the new Virto R rechargeable hearing device received strong market responses, contributing positively to growth.
Positive Outlook and Market Share Gains
Sonova maintains its outlook for the fiscal year 2025-2026, targeting 5% to 9% sales growth and 14% to 18% growth in normalized EBITA at constant exchange rates.
Negative Updates
Challenges in Cochlear Implants and Consumer Hearing
Cochlear Implants faced a 5% decline in sales due to headwinds in China, while the Consumer Hearing business saw a 12% sales decline due to weak consumer demand and lack of new product launches.
Impact of Swiss Franc Strength
The strength of the Swiss franc negatively impacted the company's financial results, reducing reported sales by CHF 107 million or 5.8% due to FX translation.
Gross Profit Margin Challenges
The gross profit margin fell by 80 basis points in local currencies due to temporary costs related to regionalizing manufacturing and logistics.
Company Guidance
During the Sonova Half Year Results 2025-2026 Conference Call, the company provided guidance for the remainder of the fiscal year. Sonova confirmed its outlook for the full year, targeting 5% to 9% growth in sales and 14% to 18% growth in normalized EBITA, both measured at constant exchange rates. The company reported first-half sales of CHF 1.8 billion, reflecting a 4.9% increase in local currencies, and a normalized EBITA of CHF 316 million, up 16% in local currencies, with a margin expansion of 180 basis points. Sonova experienced strong performance in its Hearing Instruments and Audiological Care businesses, with a combined sales growth of 7%. Despite challenges in its Consumer Hearing and Cochlear Implants segments, the company remains confident in maintaining positive momentum, driven by recent product launches such as Virto R, Infinio Ultra, and Infinio Ultra Sphere, which are expected to contribute to growth in the second half.

Sonova Holding AG Financial Statement Overview

Summary
Sonova Holding AG demonstrates strong financial performance with solid revenue growth, robust profit margins, and effective cash flow management. The company maintains a healthy balance between debt and equity, supporting its growth trajectory.
Income Statement
85
Very Positive
Sonova Holding AG demonstrates strong revenue growth with a 6.6% increase in the most recent year, alongside solid profit margins. Gross Profit Margin has remained robust at approximately 72% and Net Profit Margin at 14% for the latest fiscal year. The EBIT and EBITDA margins are healthy at 17.9% and 24%, respectively, indicating effective cost management and operational efficiency.
Balance Sheet
78
Positive
The balance sheet shows a stable structure with a Debt-to-Equity Ratio of 0.66, reflecting moderate leverage. The Return on Equity is commendable at 20.3%, indicating effective utilization of equity to generate profits. The Equity Ratio stands at 45%, suggesting a balanced approach between debt and equity financing, though there's room for improvement in reducing liabilities.
Cash Flow
80
Positive
Cash flow analysis reveals consistent positive cash generation with a Free Cash Flow Growth Rate of 5.0%. Operating Cash Flow to Net Income Ratio is strong at 1.47, suggesting efficient conversion of income into cash. The Free Cash Flow to Net Income Ratio is also healthy at 1.21, reflecting the company's ability to maintain liquidity and fund operations effectively.
BreakdownTTMDec 2025Dec 2024Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.87B3.87B3.63B3.74B3.36B2.60B
Gross Profit2.78B2.78B2.61B2.59B2.46B1.87B
EBITDA927.00M927.00M917.90M974.50M893.10M818.60M
Net Income540.50M540.50M601.00M647.50M649.00M581.00M
Balance Sheet
Total Assets5.92B5.92B5.79B5.55B5.59B5.93B
Cash, Cash Equivalents and Short-Term Investments687.10M687.10M513.80M414.80M612.00M1.77B
Total Debt1.76B1.76B1.79B1.81B1.48B1.83B
Total Liabilities3.24B3.24B3.30B3.32B3.16B3.15B
Stockholders Equity2.66B2.66B2.47B2.21B2.41B2.75B
Cash Flow
Free Cash Flow656.10M656.10M624.70M609.10M815.90M665.50M
Operating Cash Flow793.70M793.70M753.30M763.40M922.50M754.70M
Investing Cash Flow-212.70M-212.70M-234.00M-429.50M-707.00M-123.60M
Financing Cash Flow-401.80M-401.80M-415.30M-523.50M-1.37B687.60M

Sonova Holding AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price199.15
Price Trends
50DMA
217.30
Negative
100DMA
224.17
Negative
200DMA
240.51
Negative
Market Momentum
MACD
-6.81
Positive
RSI
36.12
Neutral
STOCH
23.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SOON, the sentiment is Negative. The current price of 199.15 is below the 20-day moving average (MA) of 207.84, below the 50-day MA of 217.30, and below the 200-day MA of 240.51, indicating a bearish trend. The MACD of -6.81 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 23.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SOON.

Sonova Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
CHF15.11B38.461.00%4.49%45.08%
71
Outperform
$2.97B33.0923.83%0.45%16.59%65.76%
70
Outperform
CHF4.54B23.4227.15%0.66%27.63%160.67%
68
Neutral
CHF12.41B23.782.22%3.79%-7.84%
62
Neutral
CHF1.80B28.264.57%2.15%-9.34%-37.50%
62
Neutral
CHF1.06B-1,989.807.29%-112.70%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:SOON
Sonova Holding AG
199.15
-96.51
-32.64%
CH:STMN
Straumann Holding AG
94.74
-18.77
-16.54%
CH:MOVE
Medacta Group SA
155.00
45.14
41.10%
CH:TECN
Tecan Group AG
138.90
-66.92
-32.51%
CH:YPSN
Ypsomed Holding AG
333.50
-22.61
-6.35%
CH:MED
Medartis Holding AG
81.40
25.40
45.36%

Sonova Holding AG Corporate Events

Sonova Reports Strong Growth Amidst Currency Challenges
Nov 14, 2025

Sonova Holding AG reported strong sales and profit growth for the first half of the fiscal year 2025/26, with a 4.9% increase in revenue in local currencies and a 16.0% rise in normalized EBITA. Despite unfavorable currency developments affecting results in Swiss francs, the company maintained its growth momentum through market share gains and product innovations. Organizational changes are planned to enhance customer orientation and regional responsiveness, with a focus on expanding in high-potential regions like Asia-Pacific. The company remains optimistic about continued growth, driven by new product launches and AI capabilities.

The most recent analyst rating on (CH:SOON) stock is a Hold with a CHF237.00 price target. To see the full list of analyst forecasts on Sonova Holding AG stock, see the CH:SOON Stock Forecast page.

Sonova Expands AI Leadership with New Hearing Aid Innovations
Oct 21, 2025

Sonova Holding AG has announced the expansion of its AI leadership in hearing care with the launch of the Infinio Ultra Sphere and an advanced Infinio hearing aid line at the EUHA 2025. These innovations focus on improving speech understanding in noisy environments, extending battery life, and enhancing user-friendliness with a new cerumen management system. The DEEPSONICTM chip, which mimics the human brain’s processing of acoustic information, is a key component of these products, offering exceptional speech intelligibility. The Infinio Ultra line also features improved adaptability, universal connectivity, and longer battery performance, reinforcing Sonova’s position as an innovation leader in the hearing aid industry.

The most recent analyst rating on (CH:SOON) stock is a Sell with a CHF190.00 price target. To see the full list of analyst forecasts on Sonova Holding AG stock, see the CH:SOON Stock Forecast page.

Sonova Tops Swiss Innovation Ranking for Second Year
Sep 29, 2025

Sonova has been recognized as the top innovator among Swiss Market Index companies for the second consecutive year, highlighting its commitment to innovation in the hearing solutions industry. The company has recently launched the Phonak Audéo Sphere Infinio, a groundbreaking hearing aid platform using real-time AI, and the Phonak Virto R Infinio, the smallest in-ear hearing aid, showcasing its continuous advancements in technology to improve speech understanding in noisy environments.

The most recent analyst rating on (CH:SOON) stock is a Buy with a CHF260.00 price target. To see the full list of analyst forecasts on Sonova Holding AG stock, see the CH:SOON Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 17, 2025